- Home
- CERO vs VIVS Comparison
CERO vs VIVS Comparison
Compare CERO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- VIVS
- Stock Information
- Founded
- CERO 2017
- VIVS 2007
- Country
- CERO United States
- VIVS United States
- Employees
- CERO N/A
- VIVS N/A
- Industry
- CERO
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CERO
- VIVS Health Care
- Exchange
- CERO Nasdaq
- VIVS Nasdaq
- Market Cap
- CERO 3.1M
- VIVS 3.1M
- IPO Year
- CERO N/A
- VIVS N/A
- Fundamental
- Price
- CERO $0.59
- VIVS $2.07
- Analyst Decision
- CERO Strong Buy
- VIVS
- Analyst Count
- CERO 1
- VIVS 0
- Target Price
- CERO $11.00
- VIVS N/A
- AVG Volume (30 Days)
- CERO 4.2M
- VIVS 387.4K
- Earning Date
- CERO 05-27-2025
- VIVS 05-30-2025
- Dividend Yield
- CERO N/A
- VIVS N/A
- EPS Growth
- CERO N/A
- VIVS N/A
- EPS
- CERO N/A
- VIVS N/A
- Revenue
- CERO N/A
- VIVS $122,000.00
- Revenue This Year
- CERO N/A
- VIVS $59.08
- Revenue Next Year
- CERO N/A
- VIVS $18.24
- P/E Ratio
- CERO N/A
- VIVS N/A
- Revenue Growth
- CERO N/A
- VIVS N/A
- 52 Week Low
- CERO $0.53
- VIVS $1.56
- 52 Week High
- CERO $147.00
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- CERO 36.01
- VIVS N/A
- Support Level
- CERO $0.55
- VIVS N/A
- Resistance Level
- CERO $0.62
- VIVS N/A
- Average True Range (ATR)
- CERO 0.06
- VIVS 0.00
- MACD
- CERO -0.01
- VIVS 0.00
- Stochastic Oscillator
- CERO 7.74
- VIVS 0.00
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.